Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.
Share
Why It Matters
A big bank analyst thinks Mirum Pharmaceuticals looks even better now. They raised their target price, which means they see more room for growth ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.